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Purpose: The aim was to investigate the cross-sectional association of dietary omega-3 2 
polyunsaturated fatty acids PUFA (alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), 3 
and docosahexaenoic acid (DHA)) intake with multiple physical functions, muscle mass and 4 
fat mass in older women.  5 
Method: Study subjects were 554 women from the Osteoporosis Risk Factor and Prevention 6 
Fracture Prevention Study, with dietary intake assessed with 3-day food record. Body 7 
composition was measured by dual-energy X-ray absorptiometry. Physical function measures 8 
included walking speed 10 m, chair rises, one leg stance, knee extension, handgrip strength and 9 
squat. Short physical performance battery (SPPB) score was defined based on the European 10 
working group on sarcopenia criteria.  11 
Results: The multivariable adjusted models showed statistically significant associations for 12 
dietary ALA with higher SPPB (β=0.118, P=0.024), knee extension force at baseline (β=0.075, 13 
P=0.037) and lower fat mass (β=-0.081, P=0.034), as well as longer one-leg stance (β= 0.119, 14 
P=0.010), higher walking speed (β=0.113, P=0.047), and ability to squat to the ground 15 
(β=0.110, P=0.027) at baseline. Total dietary omega-3 PUFA was  associated with better SPPB 16 
(β=0.108, P=0.039), one-leg stance (β=0.102, P=0.041) and ability to squat (β=0.110, 17 
P=0.028), and with walking speed (β=0.110, P=0.028,). However, associations for dietary EPA 18 
and DHA with physical function and body composition were not significant. 19 
Conclusion: Dietary omega-3 and ALA, but not EPA and DHA, were positively associated 20 
with muscle strength and function in older women. The intake of omega-3 and its subtypes was 21 
not associated with muscle mass. Longitudinal studies are needed to show whether omega-3 22 




Ageing is associated with progressive physical function loss, changes in body composition by 25 
increase in fat mass and loss of muscle mass. These can lead to independence loss, frailty and 26 
consequently failing to carry on with activities of daily living, mental and cognitive decline 27 
[1]. Variety of assessment tools are currently available to asses physical function decline in 28 
older people, e.g. walking speed, hand grip strength, chair rises, knee extension force which 29 
are predictors of physical capacity, falls and hospitalization [2,3], morbidity, and 30 
mortality[4,5]. These physical function assessments are also highlighted as significant 31 
components of sarcopenia [6] and Fried frailty definition [7]. Similarly, muscle mass loss in 32 
older adults has been suggested as a clinical predictor of these adverse health outcomes[8,9]. 33 
Investigating the role of diet and nutrients in preventing the onset of sarcopenia, deterioration 34 
of physical function and muscle mass loss are of high public health interest, mainly owing to 35 
the possibility of altering these factors via related interventions [10,11]. Among the 36 
components of a healthy diet, omega-3 PUFA are under focus in ageing research. The three 37 
main omega-3 PUFA are alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 38 
docosahexaenoic acid (DHA). Humans are unable to synthesize ALA, and as a result, it is 39 
essential to the diet. ALA is found mainly in plant oils such as flaxseed, soybean, and canola 40 
oils, whereas DHA and EPA are found in fish and other seafood [12]. These fatty acids and 41 
their food sources such as fish are embedded in public health recommendations for their 42 
beneficial health effects including anti-inflammatory properties [13], and they are suggested to 43 
have a role with multiple health outcomes [14] including muscle health [15,16]. Noteworthy 44 
that WHO consortium on healthy ageing 2020 suggested that more research into role of omega-45 
3 PUFA and healthy ageing are needed [17]. 46 
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Muscle mass is maintained by a balance between muscle protein synthesis and breakdown. It 47 
has been proposed that n-3 PUFAs may be linked to muscle synthesis by enhancing the muscle 48 
protein synthesis or mTOR pathway. Finding from experimental studies, suggest that total EPA 49 
and DHA contributed to muscle protein synthesis and muscle anabolic stimulation [18]. In 50 
addition, in vivo studies have reported the changes in skeletal muscle phospholipid composition 51 
which can increase the amino acid uptake by these cells, triggering muscle anabolism [18,19]. 52 
An important cause of loss of muscle mass and strength with ageing is low grade inflammation. 53 
A systematic review and meta-analysis by Tuttle et al., indicated that higher levels of 54 
circulating inflammatory cytokines are associated with lower skeletal muscle strength and 55 
muscle mass. Hence, a plausible pathway of dietary omega-3 PUFAs in prevention loss of 56 
muscle mass and strength can be reducing low grade inflammation [20-22] in older people.  57 
Observational studies provided evidence on the positive association between plasma 58 
phospholipid PUFAs with knee extension and muscle mass [23], total omega-3, DHA, EPA 59 
and ALA intakes were positively associated with peak force (all individuals and men) in crude 60 
model in study by Rossato et al. (2020) [24], which did not remain significant in the adjusted 61 
model. A large cohort study also showed an indirect positive association for higher intake of 62 
fatty fish (rich source of omega-3) and higher in grip strength [25]. Most previous studies used 63 
single muscle strength outcomes, whereas the current study provides further evidence by 64 
studying the association for omega-3 PUFAs in relation to multiple physical function measures. 65 
In addition, the systematic review and meta-analysis indicated lack of sufficient data on omega-66 
3 with muscle mass and strength [23]. The study hypothesis was that higher dietary ALA, EPA, 67 
DHA and total omega-3 PUFA intake associate with better clinical markers of muscle function 68 




Study design and participants 71 
Data for the present study were collected from the Osteoporosis Risk Factor and Prevention-72 
Fracture Prevention Study (OSTPRE-FPS), which began in 2003 in Kuopio, Finland [24]. The 73 
OSTPRE-FPS was a randomized population-based open trial with a 3-year follow-up in 3,432 74 
women (aged 66 to 71 years). The primary aim of the study was to determine whether vitamin 75 
D and calcium supplementation would be effective in preventing falls and fractures in 76 
postmenopausal women. For this sub study to investigate the effect of vitamin D and calcium 77 
supplementation on fracture prevention a sample of 750 women (375 from each of the 78 
intervention and control groups) was randomly selected from the 3,432 women at the baseline 79 
underwent detailed examination at baseline and follow-up, including measurements of body 80 
composition, clinical, physical function, and laboratory tests. At the end of the trial (n=593, 81 
79.0%), 306 (40.8%) and 287 (38.2%) subjects in the intervention and control groups of the 82 
subsample, respectively. 83 
Only at the baseline 554 (93%) women returned a valid food record at the baseline, and 39 84 
women did not return the food record, or it was incomplete. Thus, for this cross-sectional study, 85 
the final analytical data included 554 women, with available dietary and physical function 86 
variables. The power analysis was performed based on the incidence of fractures [24]. There 87 
was no a priori power analysis to calculate the size of the subsample of 750 women randomly 88 
selected from the 3,432 women at the baseline. All participants provided written permission 89 
for participation. The ethical committee of Kuopio University Hospital approved the study in 90 
October 2001. The study was registered at Clinical trials.gov by the identification 91 
NCT00592917. 92 
Dietary intake 93 
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Dietary intake was assessed by using 3-day food records. The records and instructions on 94 
completing the diary were sent to the subjects beforehand and they were asked to return the 95 
diaries on a research visit at the Kuopio Musculoskeletal Research Unit (KMRU) at the 96 
University of Kuopio. Subjects were advised to complete the diary information for 3 97 
consecutive days, including 2 weekdays and either Saturday or Sunday. The types of fats used 98 
in bread, in cooking and baking were asked separately. Any unclarities in the diaries were 99 
checked by phone calls to the subjects by a nutritionist. Intake of different fatty acids and other 100 
nutrients from food records were calculated by using the Nutrica program (version 2.5, Finnish 101 
Social Insurance Institute, Turku, Finland)[25]. 102 
Body composition measurements 103 
Height and weight of participants were measured in light indoor clothing without shoes, body 104 
mass index (BMI) was calculated by weight (kg) divided by height squared (m). Fat mass and 105 
lean mass were measured by dual-energy X-ray absorptiometry (DXA) by specially trained 106 
nurses. The DXA measurements carried out using the same Lunar Prodigy adhering to the 107 
imaging and analysis protocols provided by the manufacturer (Lunar Co., Madison, WI, USA) 108 
[26]. DXA is currently a common tool suitable for estimation of body composition in terms of 109 
evaluating the ratio between fat, muscle, and bone in different parts of the body[27]. DXA also 110 
has been showed to be superior to bioimpedance for estimation of the body composition. 111 
Relative skeletal muscle index (RSMI) was calculated as the sum of the non-fat, non-bone 112 
skeletal muscle in arms and legs divided by height squared (m2). 113 
Physical performance measurements 114 
Physical performance measures were assessed by trained nurses, including: hand grip strength 115 
(kg), number of chair rises in 30 seconds, ability to squat to ground, knee extension (kg), 116 
walking speed 10m (m/s) and tandem walk for 6m (m/s), standing with closed eyes for 10 117 
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seconds and one leg stance performance for 30 seconds; See Isanejad et al. 2016 [28] for details. 118 
Hand grip strength was measured in a controlled sitting position with a pneumatic hand-held 119 
dynamometer (Martin Vigorimeter, Germany) by calculating the mean of three successive 120 
measurements from the dominant hand.  121 
Short physical performance battery 122 
Short physical performance battery (SPPB) score was calculated using three individual 123 
measures of physical performance including walking speed 10 m (m/s), chair rises in 30 124 
seconds and one leg stance performance categorized in quartiles [6], based on European 125 
Working Group on Sarcopenia definition [6] Each quartile was scored on scale of 1-4 points 126 
with the total score ranging to 12; higher scores of SPPB indicates better performance. 127 
Confounders 128 
Confounders were selected based on our prior work and literature reviews on dietary and 129 
physical function association[29], including  age (years), energy intake (Kcal), protein intake 130 
(g/d), dietary vitamin D (µg/d), dietary calcium (mg/d), BMI (kg/m2) (or height for body 131 
composition analyses), hormone therapy (used, never used and current), smoking (smoker, 132 
nonsmokers), osteoporosis (T and Z bone mineral density score for 2SD below the reference 133 
population), alcohol consumption (g/week) from a separate questionnaire, physical activity 134 
(hours/week) and intervention group. Details of computing the final physical activity variable 135 
has been published elsewhere [30]. Among the leisure and exercise variables the most common 136 
activities reported were skiing, walking, cycling, swimming, and aerobic exercise, explaining 137 
over 90% of the weekly physical activity, which was used to form the physical activity variable. 138 
The reported amount of weekly physical activity was used to form a long-term physical activity 139 
variable by summing up the average weekly physical activity at the baseline. History of 140 
diseases and medications data were collected by self-reported questionnaire at the baseline. 141 
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Multimorbidity was defined as presence of two or more long-term health conditions, including 142 
depression, diabetes mellitus, hypertension, rheumatoid arthritis, coronary heart disease, 143 
osteoporosis, cancer, and pulmonary disease. 144 
Statistical analysis 145 
This study did not have inclusion or exclusion criteria and all women who had data on the 146 
PUFA dietary intake were included in this study. All statistical analyses were executed using 147 
SPSS software version 26 for Windows (IBM Corp., Armonk, NY). All tests were two-sided 148 
and a P value of <0.05 was considered significant. Individual characteristics were analysed 149 
using ANOVA test for continuous variables and chi-square for categorical variables and 150 
presented for dietary quartiles of omega-3 PUFA and ALA. UNIANOVA controlled for 151 
selected confounders was used to account for variation in the dependent variables across the 152 
quartiles of omega-3 PUFA and ALA. Further, linear regression analyses calculated the 153 
standard coefficient β controlled for selected confounders. 154 
We tested the normality of overlay distribution we used the Kolmogrov and Sahapiro tests in 155 
the SPSS, and tests were not significant; and fit the normal curve. 156 
Selected confounders for final analytical models were age, energy intake, protein intake, 157 
dietary vitamin D, dietary calcium, BMI (replaced with height for body composition analysis), 158 
multimorbidity, hormone therapy, smoking, alcohol consumption, physical activity per week, 159 
and osteoporosis. We also run a sensitivity analysis by including income per month as surrogate 160 
for socioeconomic status into the model, where results did not materially changed.  161 
Results 162 
The mean age was 67.8±1.8 (n=554), mean BMI was 27.4 kg/m2 and 43% of population had 163 
multimorbidity at the baseline. Analysis of baseline demographic and selected variables from 164 
self-reported questionnaires did not show significant differences according to quartiles of 165 
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dietary omega-3 PUFA and ALA (Table 1). Among dietary intake variables higher omega-3 166 
PUFA was associated with lower dietary calcium and higher vitamin D intake (Table 1). 167 
Higher ALA intake was associated with lower protein intake (g/d), calcium intake (mg/d) and 168 
vitamin D intake (μg/d). Table 2 presents results for the dietary omega-3 intakes, Alpha-169 
linolenic acid (g/d) 1.4 (0.7), Eicosapentaenoic acid (g/d) 0.12 (0.1), Docosahexaenoic acid 170 
(g/d) 0.28 (0.3). 171 
Table 3 presents the association of physical function and body composition for omega-3 PUFA 172 
and ALA quartiles. After controlling for selected confounders, higher quartile of omega-3 173 
PUFA and ALA were associated with higher SPBB score (P=0.020 and P=0.010, respectively), 174 
longer one leg stance (P=0.050 and P=0.035, respectively), faster walking speed 10m (P=0.048 175 
and P=0.005, respectively), and lower frequency of women with inability to squat to the ground 176 
(P=0.014 and P=0.004, respectively). Additionally, higher quartile for ALA was associated 177 
with lower fat mass (P=0.001), and higher grip strength (P=0.047).  178 
Table 4 shows results for the linear regression analysis controlling for selected confounders 179 
(age, energy intake, protein intake, dietary vitamin D, dietary calcium, BMI, hormone therapy, 180 
smoking, osteoporosis, alcohol consumption, physical activity hour/per week and intervention 181 
group). Both omega-3 PUFA and ALA were positively and significantly associated with SPPB 182 
(β=0.108 , P=0.039 and β= 0.118, P=0.034 , respectively), one leg stance (β=0.102, P=0.041 183 
and β= 0.119, P=0.010, respectively), walking speed (β=0.110 , P=0.028 and β= 0.113, 184 
P=0.047, respectively), and with lower inability to squat to ground (β=0.110 , P=0.028 and β=185 
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0.112, P=0.027, respectively). Also, ALA intake was positively associated with knee extension 186 
force (β=0.075, P=0.037) and inversely associated with fat mass (β= -0.081, P=0.034). Similar 187 
associations were observed using 1-SD increment of omega-3 PUFA, ALA, EPA and DHA 188 
dietary intake (data not shown). 189 
Discussion 190 
The main result of the present cross-sectional study was that dietary intake of ALA and total 191 
omega-3 PUFA were positively associated with physical function assessments, including faster 192 
walking speed 10m, better performance at one leg stance, ability to squat to the ground and 193 
SPPB. Higher ALA quartile was also associated with greater grip strength and lower fat mass. 194 
Findings showed no statistically significant association for dietary EPA and DHA with physical 195 
function assessments. 196 
Although previous studies reported association between omega-3 PUFA intake with walking 197 
speed[31,32], peak force and knee extension[33]. Robinson et al. found that fatty fish intake 198 
was the largest predictor of hand grip strength[34]. Although not directly this suggests that 199 
omega-3 PUFA may at least partially explain this association. In a cross-sectional study among 200 
French community-dwelling older adults, a higher proportion of the omega-3 PUFAs EPA and 201 
DHA in plasma was associated with a higher gait speed [35]. Similar cross-sectional result was 202 
reported among 1273 older adults involved in the InCHIANTI study, significant positive 203 
association between omega-3 PUFA with the faster completion of a 7-m walking test[36]. 204 
Recent study by Rossato et al.[37] showed that the intake of total omega-3 PUFA was 205 
positively associated with peak force in older men but not in women. The present study 206 
complemented the previous findings in only women, showing where positive association for 207 
total omega-3 and ALA was detected with a wider range of physical function outcomes 208 
including positive association with one leg stance, ability to squat and grip strength and SPPB. 209 
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In contrary, the study by Fougere [31] among 400 participants aged 75.2 (± 4.3) years, reported 210 
negative association between high levels of baseline red blood cell omega-3 PUFAs and SPPB, 211 
the reason for this negative findings was partially explained by the ceiling effect as the mean 212 
SPPB was considered particularly high (10.7 out of 12) and a narrow range could reduce that 213 
statistical power, whereas in present study SPPB mean was 7.7 out of 12.  214 
Robust assessments indicated in the RCTs for direct effects omega-3 PUFAs on muscle mass 215 
and function in the older adult population are scarce. Findings of study by Smith et al. (2015) 216 
showed that six months omega-3 PUFA therapy in sixty healthy 60–85-y-old men and women, 217 
increased thigh muscle volume, and handgrip strength, and tended to increase average 218 
isokinetic power compared to control group (receiving corn oil)[38]. Another RCT of omega 219 
3 fatty acids supplementation showed no statistically significant differences either in muscle 220 
mass or in the hand grip and time up and go tests compared to control group[39]. Identifying 221 
the seldom effect of EPA and DHA on muscle mass and strength in the elderly is not feasible 222 
based on limited studies, however, a recent meta-analysis of randomized controlled trials 223 
(RCTs) found that supplementation with both types of n-3 PUFAs (EPA and/or DHA) elicits a 224 
~ 0.33 kg increase in muscle mass. In addition, EPA and DHA have positive effect on the 225 
muscle protein synthesis or reducing oxidative stress in animal models [40,41]. 226 
. Currently lower extremity functions are the main indicator for mobility as a clinical screening 227 
tool [42], and it maybe that by ageing lower extremity function are more prone to change and 228 
perhaps influenced by external stimuli such as diet and exercise. ALA is a plant-derived n-3 229 
fatty acid that mainly exists in flaxseed, soybean, perilla, walnut, and canola oils. In healthy 230 
adults, only 5–10% and 2–5% of ALA can be converted into EPA and DHA, respectively [43]. 231 
Also, the conversion of ALA to EPA and DHA in men is estimated to be as low as <8% and 232 
<4% respectively, whilst in women it is slightly higher at 21 and 9%, respectively [44]. 233 
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Therefore, inter-individual variability should be considered in future studies and possible EPA 234 
and DHA supplementation.  235 
Our study population is characterized by a high intake of omega-3 PUFA and ALA. The 236 
analysis of 3-day food record in this study showed that OSTPRE-FPS older women consumed 237 
EPA+DHA 0.41±0.47 (g/d), ALA 1.4±0.8 g/d (corresponding to 0.83% of the mean energy 238 
intake), and total omega-3 PUFA 8.8±3.4 g/d, which all are within the range of 239 
recommendation by Nordic Nutrition recommendation 2012: minimum 1 E% from n-3 fatty 240 
acids and intake of EPA + DHA up to 200–250 mg per day. 241 
There are multiple potential mechanisms which can explain the observed association in this 242 
study. Low grade inflammation has been considered as important trigger for inflammageing 243 
occurring with aging, which is a chronic state of slightly increased plasma levels of pro-244 
inflammatory mediators, such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and C-245 
reactive protein (CRP) [45]. Although the causative link between inflammatory markers and 246 
the risk for functional decline and mortality in elderly are hard to established, strong correlation 247 
between these two have been identified in previous studies [46]. Without pronouncing the 248 
causal links between inflammatory mediator and physical function, the current literature 249 
suggests that nutritional factors and particularly omega-3 PUFA are among the biological 250 
mechanism to reduce low grade inflammation  which can play role to delay or prevent the onset 251 
of physical function decline [16,47]. Results from a study indicated that ALA decreases the 252 
plasma level of inflammatory cytokines ( TNF-alpha and  IL-6) in the elderly [40]. In addition, 253 
findings from experimental studies, although limited, suggest that omega-3 PUFA contribute 254 
to muscle protein synthesis anabolic pathway. This finding was consistent with the animal 255 
models and cell culture suggesting that omega-3 PUFA can enhance the muscle protein 256 
synthesis [48]. Current evidence also suggest that omega-3 PUFAs are potentially able to 257 
enhance the capacity of muscle cells for more permeable reaction with regard to necessary 258 
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nutrients, such as glucose and amino acids (8). The finding of this study on positive association 259 
for omega-3 PUFA, and ALA with physical function outcomes can be explained by these 260 
underlying mechanisms, however, further studies on effect of omega-3 PUFAon muscle 261 
function and muscle protein synthesis are required. Besides, the positive finding may be 262 
explained by the indirect relationship of omega-3 PUFA as they can improve blood lipid profile 263 
and heart function[49] which in turn are associated with healthy ageing [40,50]. Previously, we 264 
have published that Mediterranean and Baltic Sea diets have positive associations with 265 
improved physical function and lean mass in this data [29]. We acknowledge that only for ALA 266 
the correlation coefficients relating to Mediterranean diet (r=0.210, P<0.001) and Baltic sea 267 
diet were statistically significant (r=0.126, P=0.004), but not with EPA or DHA. Even though 268 
we cannot exclude other confounding factors it maybe suggesting that role of fatty acids should 269 
be considered more in the whole dietary approach rather than single nutrients which may 270 
explain the inconsistent results of previous studies. 271 
There are possible limitations to consider. We conducted secondary analysis on data from a 272 
RCT and and the RCT was not originally designed to investigate the associations reported here 273 
from the baseline of the study. Our study population included only relatively healthy older 274 
women from a homogenous Finnish population, thus results may not be generalized to other 275 
older populations. We controlled for multiple confounders; the probability of other lifestyle 276 
factors related to higher omega-3 PUFA intake affecting physical functions cannot be excluded. 277 
Finally, since the nature of this study is observational and using self-assessment tools such as 278 
food diary as the data source, it might be that dietary intake including omega-3 PUFA can be 279 




In conclusion, this study in older women suggests that higher omega-3 PUFA and ALA s were 282 
positively associated with measures of physical capacity (walking speed 10m, at one leg stance, 283 
ability to squat to the ground and SPPB and grip strength) but not with the muscle mass. 284 
However, there is considerable scope for future work to fully elucidate the potential of omega-285 
3 PUFA in muscle function as well as on possible gender differences of omega-3 function in 286 
men and women. 287 
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Table 1. Non-dietary characteristics and intake of energy and energy-adjusted intakes of selected nutrients in the quartiles of total omega-3 PUFA and 
alpha-linolenic acid 
Variables Quartile of total omega-3 PUFA g/d P-
value 
Quartile of dietary alpha-linolenic acid g/d P-
value 


















Age (years) a 67.8±1.8 68.0±1.8 68.0±2.0 67.6±1.9 0.283 67.8±1.8 68.0±1.9 67.8±1.8 67.8±2.0 0.723 
BMI (kg/m2) 28.7±4.5 28.6±4.5 29.7±5.0 28.1±4.9 0.752 28.7±4.3 28.7±4.7 29.2±4.7 28.6±5.2 0.979 
Physical activity h/week 1.5±1.2 1.5±1.2 1.3±1.09 1.5±1.2 0.268 4.3±2.9 3.4±3.1 4.0±2.9 4.2±3.2 0.222 
Multimorbidity c 3.8±2.0 4.0±2.1 3.9±2.3 4.2±3.2 0.825 1.6±1.2 1.4±1.1 1.4±1.1 1.3±1.2 0.405 
Years since menopause (years) 18.1±4.9 19.2±4.7 18.4±6.1 18.0±5.9 0.66 18.1±5.4 18.5±4.8 18.4±4.9 18.7±6.6 0.479 
Current hormone therapy (years) b 22.5 23.7 21.7 20.9 0.66 23.2 20.9 24.5 20.3 0.749 
Current Smoking (%) 6.6 3.6 5.9 3.0 0.574 5.8 2.9 3.7 6.7 0.343 
Income per month (euro) 866±305 863±319 828±303 905±266 0.440 828±264 844±316 860±330 870±288 0.533 
Dietary variables 
Energy (kcal/d) 1690±382 1457±325 1482±369 1646±360 0.440 1652±367 1501±370 1514±374 1607±361 0.387 
Protein (g/d) 66.9±13.0 69.7±10.8 69.3±11.6 67.5±11.5 0.736 71.6±12.7 68.0±10.6 68.8±11.7 64.9±11.2 0.001 
Calcium (mg/d) 1043±320 1050±258 965±282 959±307 0.003 1078±305 1026±270 996±286 917±296 0.001 
Vitamin D (μg/d) 6.5±4.5 7.3±3.7 8.4±4.7 8.3±5.1 0.001 8.9±5.4 7.1±4.4 7.5±4.4 7.0±3.9 0.003 
Alcohol intake per week (g/d) 8.7±4.5 10.1±4.8 10.4±16.0 10.3±7.8 0.806 10.4±3.6 10.1±4.6 8.8±5.7 10.3±3.1 0.850 
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a ANOVA analysis calculated means and standard deviations for continuous variables. b Chi-square tests calculated the n and % for categorical variables.  
c  Multimorbidity was defined as presence of two or more long-term health conditions. 
 
Table 2. Dietary omega 3 PUFAs intake  
Dietary omega 3 intake Means ± SD (n=554) 
Alpha-linolenic acid (g/d)  1.4± 0.7 
Eicosapentaenoic acid (g/d)  0.12 ± 0.1 





Table 3. Baseline physical function and body composition assessments in the quartiles of total omega-3 PUFA and alpha-linolenic acid a 
 Quartile of total dietary omega-3 PUFA g/d P for 
trend 




7.7±2.4 8.3±2.3 7.8±2.3 8.8±2.1 0.020 7.7±2.3 7.7±2.2 8.2±2.5 8.8±2.1 0.010 
Grip strength (kg) 25.9±4.6 26.1±5.1 25.6±4.5 26.4±4.7 0.672 25.9±4.4 25.8±4.5 25.7±4.9 26.7±4.6 0.047 
One leg stance 30 s  18.9±10.1 20.6±9.5 20.1±9.4 22.0±9.2 0.050 18.9±7.1 19.3±7.2 20.1±6.8 23.2±7.4 0.035 
Chair rises in 20 seconds  8.9±7.6 8.3±1.9 7.9±2.3 7.1±2.2 0.223 7.8±5.2 8.3±5.5 7.8±3.0 7.7±2.4 0.666 
Tandem walk speed 6 m 
(m/s) 
0.30±0.09 0.37±0.55 0.31±0.09 0.35±0.26 0.371 0.38±0.08 0.31±0.10 0.36±0.53 0.35±0.23 0.680 
Walking speed 10 m  
(m/s)  
1.62±0.30 1.69±0.32 1.71±0.30 1.78±0.30 0.048 1.60±0.28 1.62±0.27 1.67±0.31 1.78±0.34 0.005 
Standing with eyes closed 
10 s (%)  
0.96±0.18 1.00±0.20 1.0±0.00 0.96±0.20 0.057 0.97±0.18 0.98±0.13 0.99±0.100 1.0±0.11 0.147 
22 
 
Ability to squat to the 
ground (%)  
10 6 4 3 0.014 11 3 6 4 0.004 
Knee extension (kg) c 3.0±0.98 3.1±0.64 3.0±0.83 3.0±0.80 0.813 2.9±0.93 3.0±0.68 3.11±0.82 3.17±0.79 0.245 
Lean mass (kg) 39.7±4.4 40.0±3.7 40.0±4.4 40.7±4.3 0.715 39.8±4.0 39.8±4 40.1±4.3 40.1±4.2 0.127 
Relative muscle index (kg) 6.75±0.63 6.76±0.59 6.70±0.69 6.80±0.70 0.648 6.7±0.6 6.6±0.6 6.7±0.6 6.7±0.6 0.073 
Fat Mass (kg) 29.5±8.6 29.2±8.8 28.5±8.0 28.3±9.1 0.812 29.4±7.7 29.1±8.3 27.8±8.1 26.1±7.4 0.001 
a  UNOANOVAAdjusted for age, energy intake, protein intake, dietary vitamin D, dietary calcium, BMI, hormone therapy, smoking, 

















P a Standardized 
Coefficient β 
P a Standardized 
Coefficient β 
P a Standardized 
Coefficient β 
P a 
Short Physical Performance Battery 0.108 0.039 0.015 0.752 0.013 0.752 0.118 0.024 
Grip strength (kg) 0.018 0.679 0.022 0.983 0.024 0.592 0.013 0.578 
One leg stance 30 s  0.102 0.041 0.001 0.730 0.008 0.850 0.119 0.010 
Chair rises in 20 seconds  -0.043 0.329 -0.286 0.775 -0.013 0.487 -0.014 0.348 
Tandem walk speed 6 m (m/s) 0.035 0.451 -0.017 0.715 -0.030 0.411 0.058 0.216 
Walking speed 10 m  (m/s)  0.110 0.028 0.028 0.507 0.026 0.537 0.113 0.047 
Standing with eyes closed 10 s (%)  -0.017 0.696 -0.039 0.377 -0.038 0.387 0.003 0.943 
Ability to squat to the ground (%)  0.110 0.028 0.025 0.545 0.034 0.410 0.112 0.027 
Knee extension (kg) c 0.039 0.394 -0.096 0.039 -0.104 0.075 0.096 0.037 
Lean mass (kg) -0.001 0.976 -0.029 0.471 0.048 0.158 0.030 0.372 
Relative muscle index (kg) 0.009 0.832 0.004 0913 0.039 0.345 0.017 0.684 
Fat Mass (kg) 0.001 0.970 0.001 0.979 0.013 0.740 -0.081 0.034 
PUFA, Polyunsaturated fatty acid; add EPA, DHA and ALA 
a Adjusted for age, energy intake, protein intake, dietary vitamin D, dietary calcium, BMI, hormone therapy, smoking, osteoporosis, alcohol consumption, 
physical activity hour/per week and intervention group 
 
